Download PDF
Thromb Haemost 2023; 123(04): 482-486
DOI: 10.1055/a-2002-1931
Letter to the Editor

SARS-CoV-2 Vaccination: Long-Term Follow-Up of Pre-existing and De Novo Immune Thrombocytopenia

Marina Beltrami Moreira 
1   Division of Hematology and Medical Oncology, New York Presbyterian Hospital – Weill Cornell Medicine, New York, New York, United States
,
James B. Bussel
1   Division of Hematology and Medical Oncology, New York Presbyterian Hospital – Weill Cornell Medicine, New York, New York, United States
2   Division of Pediatric Hematology/Oncology, New York Presbyterian Hospital – Weill Cornell, New York, New York, United States
,
Eun Ju Lee
1   Division of Hematology and Medical Oncology, New York Presbyterian Hospital – Weill Cornell Medicine, New York, New York, United States
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints
Zoom Image

Authors Contribution

M. B. M. contributed to data analysis and interpretation, and manuscript writing; J. B. B. contributed to study design, data interpretation, and manuscript writing; and E-J. L. contributed to study design, data collection and interpretation, and manuscript writing.


Supplementary Material



Publication History

Received: 14 October 2022

Accepted: 17 December 2022

Accepted Manuscript online:
20 December 2022

Article published online:
09 February 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mahévas M, Moulis G, Andres E. et al. Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol 2020; 190 (04) e224-e229
    CrossrefPubMedSearch in Google Scholar
  • 2 Lee EJ, Cines DB, Gernsheimer T. et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021; 96 (05) 534-537
    CrossrefPubMedSearch in Google Scholar
  • 3 Woolley P, Tailor A, Shah R, Westwood JP, Scully M. Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia. J Thromb Haemost 2022; 20 (06) 1476-1484
    CrossrefPubMedSearch in Google Scholar
  • 4 Moulis G, Crickx E, Thomas L. et al; French Covigilance COVID-19 Vaccine-ITP Study Group. De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring. Blood 2022; 139 (16) 2561-2565
    CrossrefPubMedSearch in Google Scholar
  • 5 Rodeghiero F, Stasi R, Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11) 2386-2393
    CrossrefPubMedSearch in Google Scholar
  • 6 Lee EJ, Beltrami Moreira M, Al-Samkari H. et al. SARS-CoV-2 vaccination and immune thrombocytopenia in de novo and pre-existing ITP patients. Blood 2022; 139 (10) 1564-1574
    CrossrefPubMedSearch in Google Scholar
  • 7 Kuter DJ. Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol 2021; 195 (03) 365-370
    CrossrefPubMedSearch in Google Scholar
  • 8 Crickx E, Moulis G, Ebbo M. et al. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia. Br J Haematol 2021; 195 (05) 703-705
    CrossrefPubMedSearch in Google Scholar
  • 9 Assinger A. Platelets and infection - an emerging role of platelets in viral infection. Front Immunol 2014; 5: 649
    CrossrefPubMedSearch in Google Scholar
  • 10 Fattizzo B, Bortolotti M, Giannotta JA, Consonni D, Cantoni S, Barcellini W. Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures. Sci Rep 2022; 12 (01) 7743
    CrossrefPubMedSearch in Google Scholar